Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $10.0 million
Deal Type : Series A Financing
AgilVax Announces Expansion of Series A-1 Financing
Details : This additional investment allows AgilVax to continue generating compelling preclinical data with their monoclonal antibody-drug conjugates targeting SLC7A11 (xCT).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 16, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $10.0 million
Deal Type : Series A Financing